Design, synthesis and cytotoxicity evaluation of 1-chloromethyl-5-hydroxy-1,2-dihydro-3H-benz[e]indole (seco-CBI) dimers

Bioorganic and Medicinal Chemistry

Volumn 8, Issue 7, 2000, Pages 1607-1617

  Jia, Guofeng ^a   Lown, J William ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLOROMETHYL 5 HYDROXY 1,2 DIHYDRO 3H BENZ[E]INDOLE; ANTINEOPLASTIC AGENT; DIMER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MELANOMA; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DIVISION; CELL SURVIVAL; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0033936503     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(00)00088-2     Document Type: Article

References (35)

1. (a) Reynolds, V. L.; McGovren, J. P.; Hurley, L. H. J. Antibiot. 1986, 34, 319.
2. (b) Yasuzawa, T.; Muroi, K.; Ichimura, M.; Takahashi, I.; Ogawa, T.; Takahashi, K.; Sano, H.; Saitoh, Y. Chem. Pharm. Bull. 1995, 43, 378.
3. (a) Boger, D. L.; Johnson, D. S. Angew. Chem., Int. Ed. Engl. 1996, 35, 1439.
4. (b) Boger, D. L.; Boyce, C. W.; Garbaccio, R. M.; Goldberg, J. A. Chem. Rev. 1997, 97, 787.
5. (a) Boger, D. L.; Coleman,R. S. J. Am. Chem. Soc. 1988, 110, 4796.
6. (b) Lin, C. H.; Sun, D.; Hurley, H. L. Chem. Res. Toxicol. 1991, 4, 21.
7. (c) Mitchell, M. A.; Kelly, R. C.; Wicnienski, N. A.; Hatzenbuhler, N. T.; Williams, M. G.; Petzold, G. L.; Slighton, J. L.; Siemeniak, D. R. J. Am. Chem. Soc. 1991, 113, 8994.
8. (d) Kelly, R. C.; Gebhard, I.; Wicknienski, N.; Aristoff, P. A.; Johnson, P. D.; Martin, D. G. J. Am. Chem. Soc. 1987, 109, 6837.
9. (e) Boger, D. L.; Yun, W.; Han, N. Bioorg. Med. Chem. 1995, 3, 1429.
10. (a) Boger, D. L.; Ishizaki, T.; Wysocki, R. J. Jr.; Muck, S. A. J. Am. Chem. Soc. 1989, 111, 6461.
11. (b) Boger, D. L.; Ishizaki, T. J. Org. Chem. 1990, 55, 5823.
12. (c) Boger, D. L.; Yun, W.; Teegarden, B. R. J. Org. Chem. 1992, 57, 2873.
13. (d) Boger, D. L.; Mesini, P.; Tarby, C. M. J. Am. Chem. Soc. 1994, 116, 6461.
14. (e) Boger, D. L.; McKie, J. A. J. Org. Chem. 1995, 60, 1271.
15. (f) Aristoff, P. A.; Johnson, P. D. J. Org. Chem. 1992, 57, 6234.
16. (g) Drost, K. J.; Cava, M. P. J. Org. Chem. 1991, 56, 2240.
17. (a) Fregeau, N. L.; Wang, Y.; Pon, R. T.; Wylie, W. A.; Lown, J. W. J. Am. Chem. Soc. 1995, 117, 8917.
18. (b) Iida, H.; Lown, J. W. Recent Res. Devel. in Synth. Org. Chem. 1998, 1, 17.
19. (a) Jia, G.; Iida, H.; Lown, J. W. Heterocyclic Commun. 1998, 4, 557.
20. (b) Jia, G.; Iida, H.; Lown, J. W. Chem. Commun. 1999, 119.
21. Iida, H.; Jia, G.; Lown, J. W. Curr. Opin. Biotechnol. 1999, 10, 29, and references cited therein.
22. (a) Mitchell, M. A.; Johnson, P. D.; Williams, M. G.; Aristoff, P. A. J. Am. Chem. Soc. 1989, 111, 6428.
23. (b) Mitchell, M. A.; Kelly, R. C.; Wicniensky, N. A.; Hatzenbuhler, N. T.; Williams, M. G.; Petzold, G. L.; Slihgtom, J. L.; Siemieniak, D. R. J. Am. Chem. Soc. 1991, 113, 8994.
24. Rajski S.R., Williams R.M. Chem. Rev. 98:1998;2723.
25. Boger D.L., McKie J.A., Cai H., Cacciari B., Baraldi P.G. J. Org. Chem. 61:1996;1710.
26. Boger D.L., Han N., Tarby C.M., Boyce C.W., Cai H., Jin Q., Kitos P.K. J. Org. Chem. 61:1996;4894.
27. Owton W.M., Gallagher P.T., Juan-Montesinos A. Synth. Commun. 23:1993;2119.
28. Patel V.F., Andis S.L., Enkeme J.K., Kennedy J.H., Mohamadi F., Schultz R.M., Soose D.J., Spees M.M. J. Org. Chem. 62:1997;8868.
29. Clive D.L.J., Angoh A.G., Bennett S.M. J. Org. Chem. 52:1987;1339.
30. Boger D.L., Boyce C.W., Garbaccio R.M., Searcey M. Tetrahedron Lett. 39:1998;2227.
31. (a) Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. J. Natl. Cancer Inst. 1991, 83, 757.
32. (b) Paull, K. D.; Shoemaker, R. H.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. J. Natl. Cancer Inst. 1989, 81, 1088.
33. (c) Boyd, M. R.; Paull, K. D.; Rubinstein, L. R. In Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery. Valeriote, F. A., Corbett, T., Baker, L., Eds.; Kluwer Academic Publishers: Amsterdam, 1992; pp 11-34.
34. (a) Boger, D. L.; Santillan, Jr., A.; Searcey, M.; Jin, Q. J. Am. Chem. Soc. 1998, 120, 11554.
35. (b) Boger, D. L.; Santillan, Jr. A.; Searcey, M.; Jin, Q. J. Org. Chem. 1999, 64, 5241.